

For Immediate Release
Quintessence Biosciences, Inc.
October 22, 2007

Contact: Dr. Laura Strong
President and Chief Operating Officer
608-441-2950

Advanced Toxicology Data on Quintessence Biosciences' Lead Candidate Presented at Cancer Meeting

SAN FRANCISCO, CA AND MADISON, WI – Dr. Laura Strong, President and Chief Operating Officer at Quintessence Biosciences, Inc., presented information about the company's lead candidate QBI-139 at the International Conference on Molecular Targets and Cancer Therapeutics - the premier international meeting featuring novel cancer therapeutics - at the Moscone West Convention Center this week. Dr. Strong's poster, *Toxicology of a Potent Human RNase Variant*, provides non-clinical safety data for QBI-139.

QBI-139 is a potent anticancer agent based on the EVade™ Ribonuclease technology. The technology provides an opportunity to attack RNA, an exciting new cancer drug target, with analogs of the human pancreatic ribonuclease 1. In preclinical disease models, QBI-139 has shown an exceptional safety profile and outstanding tumor growth inhibition *in vivo* against human pancreatic, non-small cell lung, prostate, and ovarian solid tumors. Of approximately 40 different EVade™ Ribonucleases tested to date, QBI-139 had the best therapeutic index as well as the broadest efficacy in multiple tumor lines.

Quintessence projects a Phase 1 clinical trial for QBI-139 will begin in early 2008, subject to U.S. Food and Drug Administration (FDA) review.

“The toxicology results for QBI-139 strongly support continued development of this drug candidate,” said Quintessence Biosciences CEO Ralph Kauten. “Based on the broad efficacy and minimal side effects, we have great expectations that QBI-139 will lead to an efficacious cancer therapy that will be well tolerated by patients.”

About Quintessence Biosciences, Inc.

Quintessence Biosciences, Inc. is a private biopharmaceutical company focused on development of proprietary cancer therapies based on the EVade™ Ribonuclease technology. Quintessence's first product candidate, QBI-139, is anticipated to enter a Phase 1 clinical trial in early 2008. The company also has a pipeline of other EVade™ Ribonuclease products in preclinical research. For more information, visit www.quintbio.com.

About the International Conference on Molecular Targets and Cancer Therapeutics

Each year, the American Association for Cancer Research (AACR), jointly with the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC), brings together scientists and other professionals from around the world seeking to share the latest information in this field, otherwise known as molecular targets of cancer. This year more than 3,000 scientists and clinicians - from the laboratories of universities, medical centers and pharmaceutical companies worldwide - are gathering in San Francisco to present and discuss novel cancer research findings.

About Laura Strong

A National Institutes of Health predoctoral fellow, Dr. Strong earned a Ph.D. in organic chemistry at the University of Wisconsin–Madison. She holds a Bachelor of Science in Chemistry from the University of Richmond and has served as Research Assistant in the labs of Professor Russell Schmechl at Tulane University Department of Chemistry, Professor Richard Topham at University of Richmond Department of Chemistry, and Professor Laura L. Kiessling at University of Wisconsin - Madison, Departments of Chemistry and Biochemistry.

Dr. Strong was named President of Quintessence Biosciences in 2006. She received one of five *Rising Star* awards presented by the Wisconsin Biotechnology and Medical Device Associations' annual meeting in Madison, Wisconsin.